RNRama Naghshizadian

Rama Naghshizadian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rama Naghshizadian has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Abolhassan Seyedzadeh

    Department of Pediatrics, Imam Reza Hospital, Dr. Kermanshahi Hospital, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

    1 shared publication
  • Alaleh Gheissari

    Department of Pediatric Nephrology, Isfahan Research Center of Kidney Diseases. Isfahan University of Medical Sciences, Isfahan, Iran

    1 shared publication
  • Arash Abbasi

    Pediatric Chronic Kidney Disease Research Center , Gene , Cell & Tissue Research Institute , Children’s Medical Center , Tehran University of Medical Sciences , Tehran , Iran , tums.ac.ir

    1 shared publication
  • Fahimeh Askarian

    Pediatric Chronic Kidney Disease Research Center , Gene , Cell & Tissue Research Institute , Children’s Medical Center , Tehran University of Medical Sciences , Tehran , Iran , tums.ac.ir

    1 shared publication
  • Farahnak Assadi

    Department of Pediatrics, Division of Nephrology (FA), Rush University Medical Center, Chicago, IL

    1 shared publication
  • Fatemeh Ghane Sharbaf

    Department of Pediatrics, Section of Nephrology, Mashhad University of Medical Sciences, Mashhad, Iran

    1 shared publication

Latest Publications

  • Genetically Confirmed Hyperoxaluria in Iranian Children- A Multicenter Survey

    by Nakysa Hooman, Mahmood Maleknejad, Mitra Basiratnia, Marzieh Mojbafan, Alaleh Gheissari, Fahimeh Askarian, Rama Naghshizadian, Fatemeh Ghane Sharbaf, Arash Abbasi, Nahideh Ekhlasi, et al.

    Introduction. Primary hyperoxaluria (PH) is a rare autosomal recessive disorder characterized by a heterogeneous presentation that leads to kidney failure and involvement of other organs. The aim of this study was to determine the number of cases with suspected PH in Iran that have had a genetically verified diagnosis. Methods. A survey distributed among members of Iranian society of pediatric nephrology (IranSPN) to collect overall data on hyperoxaluria (HOX) in their centers, as well as those who performed whole exome sequencing (WES) or sanger sequencing genetic study. Data is presented as frequency and number blocks. Results. Nineteen out of 130 members filled out the questionnaires. About two-thirds of the responders were suspected to have HOX in the presence of recurrent multiple kidney stones. PH was genetically confirmed in 80 children above 10 years. Alanine-Glyoxylate Aminotransferase (AGXT) was the most frequent reported genetic abnormailtiy. The majority of their patients required kidney replacement therapy. Combined or sequential liver- kidney transplantation was less frequent. Conservative treatment was the only therapy applied to all children prior to end-stage kidney disease.Conclusion. This simple survey revealed that definitive diagnosis of PH occurs at older age accompanied with higher rate of kidney transplantation.

  • Efficacy of Probiotic Prophylaxis After The First Febrile Urinary Tract Infection in Children With Normal Urinary Tracts

    by S Sadeghi-Bojd, R Naghshizadian, M Mazaheri, F Ghane Sharbaf, F Assadi

    Background: Growing antibiotic resistance and debates over their efficacy for urinary tract infection (UTI) recurrence warrants studying nonantibiotic prophylaxis for preventing UTI recurrences. Methods: We randomly assigned 181 children, aged 4 months to 5 years, with a normal urinary tract after recovery from their first febrile UTI in a 1:1 ratio to receive a probiotic mixture of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum, and Bifidobacterium lactis (n = 91) or placebo (n = 90) for a total of 18 months of therapy. The primary objective was to show the superiority of probiotic prophylaxis to placebo. The primary end point was composite cure (UTI-free survival) at 18 months, and the secondary end point was the median time to first UTI recurrence. Results: The probiotics were superior to placebo with respect to the primary efficacy end point. At 18 months, composite cure was observed in 96.7% (3 of 91) of the patients in the probiotic group and 83.3% (15 of 90) of those in the placebo group (P = .02). The median time to the first incidence of UTI recurrence was 3.5 months (range, 1–4 months) and 6.5 months (range, 2–14 months) in the probiotic and placebo groups, respectively (P = .04). The main microorganism that caused recurrent UTI was Escherichia coli, followed by Klebsiella pneumoniae, and these results were not significantly different between the 2 groups. We found no specific adverse events among the participants who received the probiotic mixture during the course of therapy. Conclusions: The probiotics were more effective than placebo at reducing the risk of recurrent UTI in children with a normal urinary tract after their first episode of febrile UTI.